(Press-News.org) Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, and the Johns Hopkins Convergence Institute. The study was supported in part by the National Institutes of Health, including the National Cancer Institute’s Specialized Programs of Research Excellence.
Most new solid tumor cancer diagnoses happen in people ages 65 or older, and overall, these patients have worse cancer treatment outcomes than their younger peers. The reasons for these differences are not entirely clear. Age-related changes that make the immune system less effective could make it harder for patients’ immune systems to fight cancer cells. Newer immune system-boosting therapies may help, but questions remain about whether age-related immune changes might blunt the drugs’ effects.
The new study, published April 21 in Nature Communications, bolsters evidence that lifesaving immune checkpoint inhibitors are effective across age groups despite age-related changes in the immune response. The study identifies some key differences in the immune response to these drugs in older patients compared with younger ones that may one day help clinicians further personalize therapies and boost treatment success.
“Older patients do just as well, sometimes better than younger patients with immunotherapy treatments,” says senior author Daniel Zabransky, M.D., Ph.D., an assistant professor of oncology at the Johns Hopkins University School of Medicine. “We found clues about important pathways mediating the immune system response to immunotherapies in younger versus older patients that may help us improve the next generation of therapies or allow us to use current therapies in all patients more effectively.”
The study examined immune cells and proteins they release called cytokines in the blood of about 100 patients treated with immune checkpoint inhibitors for cancer. About half of the patients were ages 65 or older. Both groups benefited from therapy equally, but there were differences in their immune responses and immune cells.
For example, T cells are the cells that help destroy damaged cells, bacteria or viruses. In response to an infection or other threat, groups of T cells specialize to eliminate that particular foe. Some T cells are considered “inexperienced” and remain on standby to respond to future threats. These inexperienced T cells in older patients looked like “they’d been around the block,” Zabransky says, suggesting that they may be less ready to respond to threats such as cancer without additional treatments such as immune checkpoint inhibitors. These differences may make immune checkpoint inhibitors even more beneficial for older patients.
Next, Zabransky and his team want to look at differences in immune cells found inside tumors and compare them across age groups to see how they react to immunotherapies. They hope that by understanding age-related differences in immune responses to cancer therapies, they can either develop new cancer therapies better tailored to different age groups’ needs or find new ways to combine existing treatments to improve care. It’s imperative, he notes, to find ways to boost therapy effectiveness in older patients without triggering toxicities or other adverse events that can lead to poor outcomes.
“Right now, we give immune checkpoint inhibitors to patients in the same way without major consideration about how their age may influence how the immune system may recognize cancer cells,” he says. “By better understanding age-related changes that we all experience over our lifespan, we hope to identify new strategies and personalize our therapies even further based on those important patient-level factors.”
Other study authors were Chester Kao, Soren Charmsaz, Hua-Ling Tsai, Khaled Aziz, Daniel H. Shu, Kabeer Munjal, Ervin Griffin, James M. Leatherman, Evan J. Lipson, Yasser Ged, Jeannie Hoffman-Censits, Howard L. Li, Elsa Hallab, Madelena Brancati, Mari Nakazawa, Stephanie Alden, Christopher Thoburn, Nicole E. Gross, Alexei G. Hernandez, Erin M. Coyne, Emma Kartalia, Marina Baretti, Elizabeth M. Jaffee, Won Jin Ho, and Mark Yarchoan of Johns Hopkins. Researchers from Genentech Inc. and F. Hoffman-La Roche Ltd., also participated in the study.
Additional support for the study was provided by the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Swim Across America, imCORE-Genentech, the MacMillan Pathway to Independence Award, the MD Anderson GI SPORE Career Enhancement Award from the National Cancer Institute and the Maryland Cancer Moonshot Research Grant.
Lipson reports consulting or advising for Agenus, Bristol-Myers Squibb, CareDx, Eisai, Genentech, HUYA Bioscience International, Immunocore, Bio, IO Biotech, Lyvgen, Merck, Merck KGaA, Natera, Nektar, Novartis, OncoSec, Pfizer, Rain Therapeutics, Regeneron, Replimune, Sanofi-Aventis, Sun Pharma, Syneos Health. Lipson also reports institutional funding from 1104Health, Bristol-Myers Squibb, Haystack Oncology, Merck, Regeneron, and Sanofi. Lipson owns stock in Iovance. Lipson also is supported by Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research, the Barney Family Foundation, and the Laverna Hahn Charitable Trust. Brancati reports institutional grant support from Merck and consulting for Exelixis, Incyte, and AstraZeneca. Jaffe reports other support from Abmeta and Adventris, personal fees from Dragonfly, Neuvogen, Surge Tx, Mestag, HDTbio, and grants from Lustgarten, Genentech, BMS, NeoTx, and Break Through Cancer. Jaffee is also a founder, consultant and equity holder in Adventris Pharmaceuticals. Adventris Pharmaceuticals has licensed a technology described in this study and Jaffe and Johns Hopkins receive royalties related to that license. Ho reports patent royalties from Rodeo/Amgen; grants from Sanofi, NeoTX, and Riboscience; and speaking/travel honoraria from Exelixis and Standard BioTools. Yarchoan has received grant/research support (to Johns Hopkins) from Bristol-Myers Squibb, Incyte and Genentech/Roche, honoraria from Genentech/Roche, Exelixis, AstraZeneca, Replimune, Hepion, and Lantheus, and is a cofounder with equity in Adventris. Zabransky reports grant support (to Johns Hopkins) and travel from Roche/Genentech, and honoraria from Omni Health Media, Sermo, Atheneum, Escientiq, Deerfield Institute, ZoomRx, and NeuCore Bio. Johns Hopkins University manages these relationships in accordance with its conflict-of-interest policies.
END
Older adults respond well to immunotherapy despite age-related immune system differences
2025-04-21
ELSE PRESS RELEASES FROM THIS DATE:
Study reveals new genetic mechanism behind autism development
2025-04-21
Scientists from The Hospital for Sick Children (SickKids) and University of Las Vegas Nevada (UNLV) have uncovered a genetic link between autism spectrum disorder (ASD) and a rare genetic condition called myotonic dystrophy type 1 (DM1). The study, published today in Nature Neuroscience, suggests that while ASD has previously been characterized by a loss of gene function, another mechanism may be leading to the social behaviours often observed in individuals with ASD.
DM1 is an inherited condition which causes progressive muscle ...
The puberty talk: Parents split on right age to talk about body changes with kids
2025-04-21
ANN ARBOR, Mich. – Most parents agree that talking to their kids about puberty is important—but when and how to start the conversation is often less clear, a new national poll suggests.
Among the most common challenges for parents: choosing the right age to start talking about body changes and whether to explain sex, according to the University of Michigan Health C.S. Mott Children’s Hospital National Poll on Children’s Health.
Parents are evenly split in thinking it’s best to start talking about puberty before 10 years, at age 10 or when children are older.
“It’s easy to assume a child is too ...
Tusi (a mixture of ketamine and other drugs) is on the rise among NYC nightclub attendees
2025-04-21
“Tusi”, also known as “tucibí” or “pink cocaine”, is a drug concoction that emerged in Latin America and Europe within the past decade and is becoming increasingly popular in the USA. A new study published in the scientific journal Addiction estimates that in 2024, 2.7% of electronic dance music-nightclub attending adults in New York City (NYC) used Tusi in the past year, with higher use among Hispanic people and people who use other drugs.
Consumers often don’t understand what Tusi is when they take it. Tusi ...
Father’s mental health can impact children for years
2025-04-19
In popular culture, dads are stoic, sensitive and strong. So powerful is the mystique of the happy dad that celebrities, joke books – even hard seltzers – carry the label.
Real life is different. Fathers get down, sometimes debilitatingly. And as new research from Rutgers Health reveals, when paternal depression goes undiagnosed or unaddressed, the negative social and behavioral effects on children can persist for years.
In a study published in the American Journal of Preventive Medicine, Kristine Schmitz, an assistant professor of pediatrics ...
Scientists can tell healthy and cancerous cells apart by how they move
2025-04-19
Tokyo, Japan – Researchers from Tokyo Metropolitan University have found that the motion of unlabeled cells can be used to tell whether they are cancerous or healthy. They observed malignant fibrosarcoma cells and healthy fibroblasts on a dish and found that tracking and analysis of their paths can be used to differentiate them with up to 94% accuracy. Beyond diagnosis, their technique may also shed light on cell motility related functions, like tissue healing.
While scientists and medical experts have been looking at cells under the microscope for many centuries, most studies and diagnoses focus on their shape, what they contain, and where different parts are located inside. ...
Male athletes need higher BMI to define overweight or obesity
2025-04-18
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that the internationally recognised body mass index (BMI) cut-off points greatly overestimate overweight and obesity in male athletes. The study, from Italy, also proposes new cut-off points for overweight and obesity in this group.
Body mass index (BMI) is a key method for measuring people’s weight status, defining whether they have normal weight, overweight or obesity. It is easily calculated by dividing an individual’s weight in kilograms by the ...
How thoughts influence what the eyes see
2025-04-18
When you see a bag of carrots at the grocery store, does your mind go to potatoes and parsnips or buffalo wings and celery?
It depends, of course, on whether you’re making a hearty winter stew or getting ready to watch the Super Bowl.
Most scientists agree that categorizing an object — like thinking of a carrot as either a root vegetable or a party snack — is the job of the prefrontal cortex, the brain region responsible for reasoning and other high-level functions that make us smart and social. In that account, the eyes and visual regions of the brain are kind of like a security camera collecting data and processing it ...
Unlocking the genetic basis of adaptive evolution: study reveals complex chromosomal rearrangements in a stick insect
2025-04-18
LOGAN, UTAH, USA – Understanding the material basis of adaptive evolution has been a central goal in biology dating back to at least the time of Darwin. One focus of current debates is whether adaptive evolution relies on many mutations with small and roughly equal effects, or is it driven by one or a few mutations that cause major changes in traits.
Chromosomal rearrangements where large chunks of chromosomes are inverted, moved, deleted or duplicated, provide a possible source for such large-scale “macromutations.” However, characterizing chromosomal rearrangements with commonly tried ...
Research Spotlight: Using artificial intelligence to reveal the neural dynamics of human conversation
2025-04-18
What were you investigating?
We investigated how our brains process language during real-life conversations. Specifically, we wanted to understand which brain regions become active when we're speaking and listening, and how these patterns relate to the specific words and context of the conversation.
What methods did you use?
We employed artificial intelligence (AI) to take a closer look at how our brains handle the back-and-forth of real conversations. We combined advanced AI, specifically language models like ...
Could opioid laws help curb domestic violence? New USF research says yes
2025-04-18
TAMPA, Fla. (April 18, 2025) – A new study led by the University of South Florida reveals opioid control policies may offer broader public health benefits, including reducing instances of domestic violence. As policymakers continue to grapple with the opioid epidemic, this study highlights the power of research to inform effective public policy.
The research conducted by USF doctoral student Minglu Sun and Andrei Barbos, associate professor of economics, underscores how opioid abuse can cause a powerful ripple effect across society.
Published in Health Economics, the study analyzes the impact on the prevalence of domestic violence in Mandatory Access Prescription ...